Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Jung, Hyun Ae, Maeng, Chi Hoon, Kim, Moonjin, Kim, Sungmin, Jung, Chul Won, Jang, Jun Ho
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2015
Pynciau:
Clinical Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599296/
https://ncbi.nlm.nih.gov/pubmed/25938546
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg